Hepatoprotective effects of the long-acting fibroblast growth factor 21 analog PF-05231023 in the GAN diet-induced obese and biopsy-confirmed mouse model of nonalcoholic steatohepatitis
Malte Hasle Nielsen, Matthew P. Gillum, Niels Vrang, Jacob Jelsing, Henrik H. Hansen, Michael Feigh, Denise Oró
2023American Journal of Physiology-Gastrointestinal and Liver Physiology19 citationsDOIOpen Access PDF
Abstract
It is unclear if long-acting FGF21 analogs have antifibrotic efficacy in NASH. We therefore profiled the clinically relevant FGF21 analog PF-05231023 in a translational diet-induced obese and biopsy-confirmed mouse model of NASH. We found PF-05231023 to exert hepatoprotective effects as indicated by notable improvements in plasma markers and histological hallmarks of NASH, including improved fibrosis stage. Collectively, the present study supports the continued exploration of long-acting FGF21 analogs for the treatment of NASH and other fibrotic diseases.
Topics & Concepts
Nonalcoholic fatty liver diseaseFibrosisSteatohepatitisLiver biopsyFGF21Internal medicineSteatosisFatty liverEndocrinologyMedicineBiopsyLiver diseasePathologyBiologyDiseaseFibroblast growth factorReceptorFibroblast Growth Factor ResearchKruppel-like factors researchLiver Disease Diagnosis and Treatment